{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:41Z","timestamp":1792800881703,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.7759\/cureus.115529","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:20:22Z","timestamp":1788200422000},"source":"Crossref","is-referenced-by-count":1,"title":["Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Abdulaziz I","family":"Alghulayqah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu G","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, et al.. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011, 183:788-824. 10.1164\/rccm.2009-040GL","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley B","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011, 183:431-40. 10.1164\/rccm.201006-0894CI","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0158-2019","article-title":"Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review","volume":"29","author":"Khor YH","year":"2020","unstructured":"Khor YH, Ng Y, Barnes H, Goh NS, McDonald CF, Holland AE. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev. 2020, 29:10.1183\/16000617.0158-2019","journal-title":"Eur Respir Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001814","article-title":"Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines","volume":"23","author":"Cottin V","year":"2014","unstructured":"Cottin V, Crestani B, Valeyre D, et al.. Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. Eur Respir Rev. 2014, 23:193-214. 10.1183\/09059180.00001814","journal-title":"Eur Respir Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of nintedanib","volume":"58","author":"Wind S","year":"2019","unstructured":"Wind S, Schmid U, Freiwald M, et al.. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019, 58:1131-47. 10.1007\/s40262-019-00766-0","journal-title":"Clin Pharmacokinet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin L","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015, 45:1434-45. 10.1183\/09031936.00174914","journal-title":"Eur Respir J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-014-0157-3","article-title":"Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"15","author":"Hostettler KE","year":"2014","unstructured":"Hostettler KE, Zhong J, Papakonstantinou E, et al.. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014, 15:157. 10.1186\/s12931-014-0157-3","journal-title":"Respir Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi L","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al.. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014, 370:2071-82. 10.1056\/NEJMoa1402584","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.04.005","article-title":"Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy","volume":"152","author":"Spagnolo P","year":"2015","unstructured":"Spagnolo P, Maher TM, Richeldi L. Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. Pharmacol Ther. 2015, 152:18-27. 10.1016\/j.pharmthera.2015.04.005","journal-title":"Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-015-0276-5","article-title":"Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis","volume":"16","author":"Corte T","year":"2015","unstructured":"Corte T, Bonella F, Crestani B, et al.. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015, 16:116. 10.1186\/s12931-015-0276-5","journal-title":"Respir Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty KR","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al.. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019, 381:1718-27. 10.1056\/NEJMoa1908681","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01487-0","article-title":"Nintedanib: a review in fibrotic interstitial lung diseases","volume":"81","author":"Lamb YN","year":"2021","unstructured":"Lamb YN. Nintedanib: a review in fibrotic interstitial lung diseases. Drugs. 2021, 81:575-86. 10.1007\/s40265-021-01487-0","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01598-0","article-title":"Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease","volume":"21","author":"Schmid U","year":"2021","unstructured":"Schmid U, Weber B, Sarr C, Freiwald M. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. BMC Pulm Med. 2021, 21:244. 10.1186\/s12890-021-01598-0","journal-title":"BMC Pulm Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder S","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023, 8:262. 10.1038\/s41392-023-01469-6","journal-title":"Signal Transduct Target Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00912-y","article-title":"Management of peripheral edema in patients with MET exon 14-mutated non-small cell lung cancer treated with small molecule met inhibitors","volume":"17","author":"Nishio M","year":"2022","unstructured":"Nishio M, Kato T, Toyozawa R, Hida T. Management of peripheral edema in patients with MET exon 14-mutated non-small cell lung cancer treated with small molecule met inhibitors. Target Oncol. 2022, 17:597-604. 10.1007\/s11523-022-00912-y","journal-title":"Target Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10729","article-title":"Severe periorbital edema secondary to STI571 (Gleevec)","volume":"95","author":"Esmaeli B","year":"2002","unstructured":"Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, Talpaz M. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002, 95:881-7. 10.1002\/cncr.10729","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111343","article-title":"VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd","volume":"209","author":"Sun Z","year":"2012","unstructured":"Sun Z, Li X, Massena S, et al.. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J Exp Med. 2012, 209:1363-77. 10.1084\/jem.20111343","journal-title":"J Exp Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba T","year":"2007","unstructured":"Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007, 96:1788-95. 10.1038\/sj.bjc.6603813","journal-title":"Br J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann JT","year":"2009","unstructured":"Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009, 10:470-81. 10.2174\/138920009788897975","journal-title":"Curr Drug Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0521-0","article-title":"Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study","volume":"10","author":"Liu X","year":"2017","unstructured":"Liu X, Qin S, Wang Z, et al.. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017, 10:153. 10.1186\/s13045-017-0521-0","journal-title":"J Hematol Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48593-4","article-title":"Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis","volume":"9","author":"Kato M","year":"2019","unstructured":"Kato M, Sasaki S, Nakamura T, et al.. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci Rep. 2019, 9:12062. 10.1038\/s41598-019-48593-4","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2018.0091","article-title":"Korean guidelines for diagnosis and management of interstitial lung diseases: Part 2. idiopathic pulmonary fibrosis","volume":"82","author":"Lee SH","year":"2019","unstructured":"Lee SH, Yeo Y, Kim TH, et al.. Korean guidelines for diagnosis and management of interstitial lung diseases: Part 2. idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul). 2019, 82:102-17. 10.4046\/trd.2018.0091","journal-title":"Tuberc Respir Dis (Seoul)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522033-nintedanib-associated-generalized-body-swelling-in-a-patient-with-idiopathic-pulmonary-fibrosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:20:23Z","timestamp":1788200423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522033-nintedanib-associated-generalized-body-swelling-in-a-patient-with-idiopathic-pulmonary-fibrosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.115529","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}